Bayer Grants4Apps® is calling all mature teams, startups and companies that have a solution ready to go. The new Dealmaker is all about quality facetime between you and Grants4Apps' experts for one full day. If there is a match, you will be invited to Berlin to pitch your solution, discuss collaboration options and close a deal. Find out, if there is a mutual interest to start a bigger journey.

With the founding of BI X as independent subsidiary Boehringer Ingelheim will focus on breakthrough innovative digital solutions in healthcare from idea to pilot. The start-up will work closely together with all three business units of the company - Human Pharma, Animal Health and Biopharmaceuticals.

Novartis today announced that it will present 19 scientific abstracts at the 59th Annual Scientific Meeting of the American Headache Society (June 8-11, 2017, Boston, USA). This includes a new analysis from a pivotal study highlighting the efficacy of AMG 334 (erenumab) in patients with 15 or more headache days a month (chronic migraine) and a recent history of acute migraine medication overuse.

Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the phase III ALEX study showed Alecensa® (alectinib) significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by more than half (53%) compared to crizotinib when given as initial (first-line) treatment for people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (hazard ratio (HR)=0.47, 95% CI: 0.34-0.65, p<0.0001).

AstraZeneca has entered an agreement with Grünenthal for the global rights to Zomig (zolmitriptan) outside Japan. Zomig is indicated for the acute treatment of migraines and cluster headaches, an area of medicine outside AstraZeneca's strategic focus.

For the second year in a row, Lyfebulb and Novo Nordisk will support international patient entrepreneurs who develop innovative ideas and concepts aimed to positively empower and impact the lives of people living with type 1 or type 2 diabetes - and ultimately our societies. The Lyfebulb-Novo Nordisk Innovation Summit is based on the Lyfebulb Entrepreneur Circle, which was established in 2015.

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to tafamidis, the company's investigational treatment for transthyretin cardiomyopathy (TTR-CM). This rare disease is associated with progressive heart failure and is universally fatal.(1,2,3) Currently in Phase 3 clinical development for TTR-CM, tafamidis is being evaluated for its potential to reduce mortality and cardiovascular-related hospitalizations.(4)